| Literature DB >> 24520460 |
Turgut Aydin1, Mustafa Kara2, Turktekin Nurettin3.
Abstract
BACKGROUND: This study assessed the relationship between endometrial thickness on day of human chorionic gonadotropin (hCG) administration and in vitro fertilizationintracytoplasmic sperm injection (IVF-ICSI).Entities:
Keywords: Endometrial Thickness; IVF-ICSI; Pregnancy Rate
Year: 2013 PMID: 24520460 PMCID: PMC3850332
Source DB: PubMed Journal: Int J Fertil Steril ISSN: 2008-0778
Fig 1Clinical pregnancy rates according to the endometrial line. EL; endometrial line.
Comparison of IVF-ICSI outcomes according to endometrial thickness on hCG day
| Group 1 (N=14) | Group 2 (N=177) | Group 3 (N=366) | Group 4 (N=36) | |
|---|---|---|---|---|
| 10.1 ± 6.6 | 9.4 ± 5.8 | 10.8 ± 7.3 | 11.4 ± 7.6 | |
| 1.3 ± 0.5 | 1.3 ± 0.6 | 1.2 ± 0.3 | 1.4 ± 0.6 | |
| 64.5 (91/141) | 65.6 (1105/1685) | 68.2 (2541/3724) | 68.0 (273/398) | |
| 60.2 (85/141) | 63.0 (1063/1685) | 64.0 (2384/3724) | 61.0 (243/398) | |
| 11.1 (2/18)* | 20.9 (82/391)* | 24.3 (188/771)* | 24.4 (19/78)* | |
| 14.3 (2/14)* | 45.7 (81/177)* | 48.6 (178/366)* | 47.2 (17/36)* | |
| 7.1 (1/14) * | 35.5 (63/177)* | 43.9 (161/366)* | 41.7(15/36)* | |
RON; Retrieved oocyte number, TEN; Transferred oocyte number, FR; Fertilization rate, CR; Cleavage rate, IR; Implantation rate, CPR; Clinical pregnancy rate and OPR; Ongoing pregnancy rate. Group 1; Endometrial line <7 mm,Group 2; Endometrial line 7-10 mm, Group 3; Endometrial line 10-14 mm and Group; Endometrial line >14 mm.
Values are mean ± SD and *; P<0.05.
Distribution of endometrial thickness according to stimulation protocol
| Group 1 | Group 2 | Group 3 | Group 4 | |||||
|---|---|---|---|---|---|---|---|---|
| N (%) | EL (mm) | N (%) | EL (mm) | N (%) | EL (mm) | N (%) | EL (mm) | |
| 0 | - | 38 (21.5) | 9.3 ± 1.2a | 86 (23.5) | 13.1 ± 1.6a | 11 (30.5) | 17.4 ± 2.1 | |
| 14 (100) | 6.5 ± 0.6 | 139 (78.5) | 7.8 ± 0.9b | 280 (76.5) | 11.2 ± 1.1b | 25 (69.5) | 16.3 ± 1.8 | |
Thickness is presented as mean ± SD. EL; Endometrial line, n; Number of patients, AP; Agonist protocol and AnP; Antagonist protocol.
a,b; P<0.05.
Distribution of patients’ characteristics
| Group 1 (N=14) | Group 2 (N=177) | Group 3 (N=366) | Group 4 (N=36) | P value | |
|---|---|---|---|---|---|
| 27 ± 4.5 | 25.6 ± 3.9 | 27.3 ± 4.8 | 28.6 ± 5.7 | Ns | |
| 5.7 ± 1.1 | 6.7 ± 1.3 | 5.9 ± 1.4 | 4.9 ± 1.1 | Ns | |
| 8.7 ± 2.1 | 7.4 ± 1.8 | 7.7 ± 1.5 | 7.0 ± 1.1 | Ns | |
| 47 ± 10.5 | 44 ± 9.7 | 41 ± 8.5 | 50.7 ± 12.5 | Ns | |
| 9.0 ± 5.2 | 7.9 ± 4.7 | 6.9 ± 4.3 | 8.0 ± 3.3 | Ns | |
| 24.8 ± 4.9 | 26.4 ± 5.4 | 28.4 ± 5.5 | 25.2 ± 6.1 | Ns | |
Ns; Nonsignificant, DI; Duration of infertility, Bas. FSH; Basal FSH, Bas. E2; Basal E2, AFC; Antral follicle count and BMI; Body mass index.
Group 1; Endometrial line <7 mm, Group 2; Endometrial line 7-10 mm, Group 3; Endometrial line 10-14 mm and Group 4; Endometrial line >14 mm.